WO2006067847A1 - フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法 - Google Patents
フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法 Download PDFInfo
- Publication number
- WO2006067847A1 WO2006067847A1 PCT/JP2004/019261 JP2004019261W WO2006067847A1 WO 2006067847 A1 WO2006067847 A1 WO 2006067847A1 JP 2004019261 W JP2004019261 W JP 2004019261W WO 2006067847 A1 WO2006067847 A1 WO 2006067847A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- fucose
- gene
- antibody
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
Definitions
- the present invention relates to a method for producing a recombinant protein, particularly an antibody, using a cell in which the function of a fucose transporter is inhibited.
- An antibody can exert an antitumor effect by ADCC (antibody dependent cytotoxicity) activity or CDC (complement dependent cytotoxicity) activity. It is known that an antibody is a glycoprotein to which a sugar chain is bound, and the strength of the cytotoxic activity of the antibody can vary depending on the type and amount of the sugar chain bound to the antibody. In particular, it has been reported that the amount of fucose bound to an antibody is strongly related to the strength of cytotoxic activity (see Non-Patent Document 1). Furthermore, in order to obtain an antibody with enhanced cytotoxic activity, a recombinant antibody that does not contain fucose is engineered so as not to express an enzyme that catalyzes the binding of fucose to a sugar chain during antibody production. There has been a report on a method for producing the film (see Patent Document 1).
- Non-Patent Document 1 Shields et al., J Biol Chem., 277 (30), 26733-26740, 2002
- Patent Document 1 International Publication No. WO00 / 61739
- An object of the present invention is to provide a method for producing a recombinant protein in which fucose binding is lost or reduced easily and reliably.
- an object of the present invention is to provide a method for producing an antibody in which fucose binding is lost or reduced and cytotoxic activity is enhanced.
- Another object of the present invention is to provide a host cell for producing such a protein. Means for solving the problem
- the present inventors By disrupting both fucose transporter genes on the chromosome, the present inventors inhibit uptake of fucose into the Golgi apparatus, resulting in inhibition of fucose attachment to the antibody.
- the present invention was completed by preparing cells in which one gene of both fucose transporters on the chromosome was disrupted.
- the present invention is as follows.
- a method for inhibiting addition of fucose to a protein comprising artificially suppressing the expression of both fucose transporter genes on a chromosome when producing a recombinant protein using cells.
- the present invention provides a cell in which the expression of both fucose transporter genes on a chromosome is artificially suppressed, and when the cell is used for protein production, it does not have fucose and is recombinant. Protein can be produced.
- the fucose-free! / ⁇ recombinant protein has reduced cytotoxic activity and is particularly advantageous for recombinant antibodies used as antibody drugs.
- FIG. 1 is a diagram showing the structures of three types of targeting vectors.
- FIG. 2 A diagram showing the structure of bands that appear after cleavage with Bgl II after the first knockout.
- FIG. 3 is a diagram showing the results of Southern plot analysis of the first-stage knockout.
- FIG. 4 is a graph showing the homologous recombination efficiency of the second-stage knockout.
- FIG. 5 shows the results of Southern plot analysis of a fucose transporter gene-deficient strain.
- FIG. 6 shows the results of fucose expression analysis of a fucose transporter gene-deficient strain (wild / KO).
- FIG. 7 shows the results of fucose expression analysis of a fucose transporter gene-deficient strain (KO / KO). BEST MODE FOR CARRYING OUT THE INVENTION
- the fucose transporter refers to a polypeptide having fucose transport activity.
- the fucose transporter when expressed on the cell membrane, the fucose transporter is usually intracellular.
- the fucose transporter is expressed on the Golgi membrane, the fucose is usually taken into the Golgi body.
- a preferred fucose transporter is a Chinese nominster fucose transporter, more preferably a fucose transporter having the amino acid sequence set forth in SEQ ID NO: 2.
- SEQ ID NO: 1 shows the base sequence of the Chinese nomstar fucose transporter gene.
- the Golgi body mainly incorporates fucose into the Golgi body via the fucose transporter present on the Golgi membrane, the function of the fucose transporter is inhibited, so that the fucose into the Golgi body. Can be inhibited, and the amount of fucose incorporated into the Golgi body can be reduced.
- Inhibiting the function of a fucose transporter of a cell means reducing or eliminating the fucose transport activity of the fucose transporter.
- the function of the fucose transporter in the cell may be inhibited by any method.
- the method of inhibiting the expression of the fucose transporter is preferred.
- fucose transporter is not particularly limited as long as the number of fucose transporters having normal transport ability is decreased, but fucose transporter using a targeting vector targeting fucose transporter, etc. It is preferable to delete (knock out) the gene coding for (fucose transporter gene).
- cells have fucose transporter genes on both chromosomes, but cells in which the function of the fucose transporter of the present invention is inhibited are deficient in both fucose transporter genes on the chromosome. is doing.
- the cell in which the function of the fucose transporter of the present invention is inhibited is not particularly limited as long as two fucose transporter genes on the chromosome are deleted, but the fucose transporter gene present on the chromosome is not limited. It is preferred that all are deleted. For example, if there are 3 fucose transporter genes on a chromosome, 3 fucose transporter genes Is preferred to be missing,. Whether or not all fucose transporter genes on the chromosome are deleted can be determined by using, for example, the Southern plot analysis described in the Examples or the FISH method.
- the protein produced by the production method of the present invention may be any protein, but is usually a glycoprotein, preferably an antibody.
- the type of antibody produced by the method of the present invention is not particularly limited, and it is possible to reduce mouse antigens, rat antibodies, rabbit antibodies, Hedge antibodies, camel antibodies, human antibodies, etc., and heteroantigenicity against humans.
- a recombinant antibody artificially modified for the purpose such as a chimeric antibody or a humanized antibody, can be used as appropriate.
- the recombinant antibody can be produced using a known method.
- a chimeric antibody is an antibody that has the constant regions of a heavy chain and a light chain of a human antibody, such as a heavy chain and a light chain of a mouse antibody, and a DNA encoding the variable region of a mouse antibody.
- a human antibody is also referred to as a reshaped human antibody, which is a non-human mammal, for example, a complementarity determining region (CDR) of a mouse antibody transplanted to the complementarity determining region of a human antibody.
- CDR complementarity determining region
- the general genetic recombination method is also known. Specifically, a DNA sequence designed to link the CDR of a mouse antibody and the framework region (FR) of a human antibody was prepared with several overlapping regions at the end. Oligonucleotide force is also synthesized by PCR.
- the obtained DNA is obtained by ligating with the DNA encoding the constant region of a human antibody, then incorporating it into an expression vector, introducing it into a host and producing it (European patent application publication number EP 239400, international patent application). Publication number WO 96/02576).
- the human antibody FR to be ligated via CDR is selected such that the complementarity determining region forms a good antigen-binding site. If necessary, amino acid in the framework region of the variable region of the antibody may be substituted so that the complementarity determining region of the reshaped human antibody forms an appropriate antigen-binding site (Sato, K. et al. , Cancer Res, 1993, 53, 851-856.).
- a method for obtaining a human antibody is also known.
- human lymphocytes are sensitized in vitro with the desired antigen or cells expressing the desired antigen, and the sensitized lymphocytes are fused with human myeloma cells, such as U266, to the antigen. It is also possible to obtain a desired human antibody having the binding activity (see Japanese Patent Publication No. 59878).
- a desired human antibody can be obtained by immunizing a transgenic animal having all repertoires of human antibody genes with a desired antigen (International Patent Application Publication Nos. WO 93/12227, WO 92/03918, WO 94/02602, WO 94/25585, WO 96/34096, WO 96/33735).
- variable region of a human antibody can be expressed as a single chain antibody (scFv) on the surface of the phage by the phage display method, and a phage that binds to the antigen can be selected.
- scFv single chain antibody
- the DNA sequence encoding the variable region of the human antibody that binds to the antigen can be determined. If the DNA sequence of scFv that binds to the antigen is clarified, an appropriate expression vector can be prepared based on the sequence to obtain a human antibody.
- the antibody may be a low molecular weight antibody such as an antibody fragment or a modified antibody as long as it can bind to an antigen.
- antibody fragments include Fab, F (ab '), Fv
- a diabody is a dimer formed by linking two fragments (for example, scFv, etc.) in which a variable region and a variable region are linked with a linker (eg, a fragment constituting Diabody). Contains two VLs and two VHs (P. Holliger et al., Proc. Natl. Acad. Sci.
- Antibodies modified with various molecules such as polyethylene glycol (PEG) can also be used as modified antibodies. It is also possible to bind a cytotoxic substance such as a radioisotope, a chemotherapeutic agent, or a bacterial-derived toxin to the antibody, and a radiolabeled antibody is particularly useful. Such a modified antibody can be obtained by chemically modifying the obtained antibody. Antibody modification methods have already been established in this field.
- PEG polyethylene glycol
- a recombinant polypeptide can be produced by a known method known to those skilled in the art.
- a DNA encoding a polypeptide is incorporated into an appropriate expression vector, and this is introduced into an appropriate host cell.
- the transformant obtained is recovered, and an extract is obtained.
- Purified and prepared by subjecting to chromatography such as gel filtration, or affinity chromatography in which an antibody against the polypeptide of the present invention is immobilized on the column, or by combining a plurality of these columns. Is possible.
- the protein when expressed in a host cell (eg, animal cell or E. coli) as a fusion polypeptide with dartathione S-transferase protein or as a recombinant polypeptide to which a plurality of histidines are added.
- a host cell eg, animal cell or E. coli
- the expressed recombinant polypeptide can be purified using a daltathion column or a nickel column. After purification of the fusion polypeptide, if necessary, a region other than the target polypeptide can be cleaved with thrombin or factor Xa to remove it.
- the protein produced by the production method of the present invention is preferably an antibody whose cytotoxic activity is affected by bound fucose.
- An antibody gene is incorporated into an appropriate vector, which is introduced into a host, and genetic recombination is performed.
- Methods for producing antibodies using techniques are well known to those skilled in the art (eg Carl, AK Borrebaeck, James, W. Larrick, THERAPEUTIC MONOCLONAL
- the present invention includes a host cell capable of producing a foreign protein, wherein the expression of both fucose transporter genes present in the chromosome is artificially suppressed.
- exogenous protein refers to a protein not derived from the cell itself.
- the host cell is not particularly limited.
- a cell in which a sugar is added to the recombinant protein when the recombinant protein is expressed can be used.
- various animal cells can be used, and CHO cells are preferable.
- CHO cells in which the fucose transporter gene has been knocked out can be preferably used.
- Animal cells include mammalian cells such as CH0 (J.
- CHO cells include dhfr-CHO (Proc. Natl. Acad. Sci. USA (1980) 77, 4216-4220) and CHO K-1 (Proc. Natl. Acad.), which are CHO cells deficient in the DHFR gene. Sci. USA (1968) 60, 1275) can be exemplified. In animal cells, CHO cells are particularly preferred for the purpose of mass expression.
- vectors include mammalian-derived expression vectors (eg, For example, pcDNA3 (manufactured by Invitrogen), pEGF- BOS (Nucleic Acids. Res.
- insect cells for example, “Bac-to- BAC baculovairus expression system "(manufactured by Gibco BRL), pBacPAK8), plant-derived expression vectors (eg, ⁇ 1, pMH2), animal virus-derived expression vectors (eg, pHSV, pMV, pAdexLcw), retrovirus-derived expression vectors (eg, pZIPneo), yeast-derived expression vectors (for example, “Pichia Expression Kit J (manufactured by Invitrogen), pNVll, SP-Q01), Bacillus subtilis-derived expression vectors (for example, pPL608, pKTH50), etc.
- insect cells for example, “Bac-to- BAC baculovairus expression system "(manufactured by Gibco BRL), pBacPAK8), plant-derived expression vectors (eg, ⁇ 1, pMH2), animal virus-derived expression vectors (eg, pHSV,
- a promoter usually required for expression in cells such as the SV40 promoter (Mulligan et al., Nature (1979) 277, 108), MMLV-LTR promoter, EF1 ⁇ promoter one (Mizushima et al., Nucleic Acids Res. (1990) 18, 5322), CMV promoter, etc., and genes for selecting transformation into cells ( For example, it is more preferable if it has a drug (drug resistance gene that can be distinguished by neomycin, G418, etc.).
- vectors having such characteristics include pMAM, pDR2, pBK-RSV, pBK-CMV, pOPRSV, and pOP13.
- the gene when the gene is stably expressed and the purpose is to amplify the copy number of the gene in the cell, the DHFR gene that complements the CHO cell lacking the nucleic acid synthesis pathway is used. And a method of amplifying with methotrexate (MTX), and for the purpose of transient expression of the gene,
- COS cells having a gene expressing SV40 T antigen on the chromosome can be used to transform with a vector having SV40 replication origin (such as pcD).
- a replication origin such as a poliovirus, adenovirus, or ushipapilloma virus (BPV) can also be used.
- the expression vector can be used as a selection marker for aminoglycoside transferase (APH) gene, thymidine kinase (TK) gene, E.
- the vector is introduced into the host cell by, for example, the calcium phosphate method, the DEAE dextran method, the method using the cationic ribosome DOTAP (manufactured by Boehringer Mannheim), the electoral position method, the lipofussion method, etc. Is possible.
- the culture of the cells can be performed according to a known method.
- DMEM, MEM, RPMI1640, IMDM can be used as a culture medium for animal cells.
- serum supplements such as fetal calf serum (FCS) can be used in combination, or serum-free culture may be performed.
- FCS fetal calf serum
- the pH during cultivation is preferably about 6-8. Cultivation is usually carried out at about 30-40 ° C for about 15-200 hours, with medium exchange, aeration, and agitation as necessary.
- Examples of cells in which the expression of both fucose transporter genes on the chromosome is artificially suppressed include cells in which both of the fucose transporter genes present on the chromosome are disrupted.
- Gene disruption refers to suppressing the expression of a gene by performing partial deletion, substitution, insertion, addition or the like on the base sequence of the gene.
- suppression of gene expression includes the case where the gene itself is expressed but the gene encoding a protein having a normal function is not expressed.
- a cell in which a gene encoding a fucose transporter is disrupted usually has a significant decrease in the amount of fucose present in the Golgi body as compared to the cell because the fucose transporter gene is disrupted.
- the ability to transport fucose is reduced or lost, or the activity of fucose uptake into the Golgi apparatus in the cell is reduced or lost.
- the amount of fucose in the Golgi body can be measured by isolating the Golgi body from cells and extracting sugar, followed by antigen-antibody reaction, sugar-lectin binding reaction, liquid chromatography, electrophoresis, and the like.
- the fucose transport ability in the cell and the fucose uptake activity into the Golgi apparatus in the cell can be determined, for example, by using fucose labeled with a fluorescent substance or a radioisotope.
- the gene can be disrupted, for example, by homologous recombination.
- the homologous recombination method is a method in which only a target gene is arbitrarily modified by homologous gene recombination between a gene on a chromosome and foreign DNA, and the purpose of dividing a sequence encoding a protein is as follows. Then insert another DNA sequence into the exon of the gene.
- a selectable marker such as a neomycin resistance gene derived from bacteria is generally used as the sequence that disrupts the gene.
- a targeting vector may be designed and produced based on the sequence information of the fucose transporter gene described in the present specification, and the fucose transporter gene to be destroyed can be homologously recombined using the targeting vector.
- a substitution vector has a homologous region linked to the 5 ′ and 3 ′ side of the mutation to be introduced, a marker for positive selection, a restriction enzyme site for linearizing the vector outside the homologous region, It may contain a marker for negative selection, a restriction enzyme cleavage site for mutation detection, etc., located outside the homologous region.
- Targeting vector is Kenichi Yamamura et al., Transgenic Animal Kyoritsu Shuppan Co., Ltd. March 1, 1997, Shinichi Aizawa Gene of mutant mice using gene targeting ES cells Bio Manual Series 8 Yodosha 1995, Hogan et al.
- the targeting vector may be either an insertion type or a substitution type.
- Recombination can also be caused by targeting using the Cre-lox system. Targeting using the Cre-lox system can be performed, for example, according to the method described in JP-T-11-503015.
- Homologous recombination As a method for selecting homologous recombinants that have undergone, known selection methods such as positive selection, promoter selection, negative selection, and poly A selection may be used. The identification of homologous recombinants can be carried out using either the PCR method or the Southern blotting method.
- cells in which the fucose transporter gene of the present invention has been disrupted can be obtained by randomly introducing mutations into cells as long as both of the two pairs of fucose transporters of the chromosome are defective.
- a gene disruption vector containing a marker is randomly introduced into the genome of a cell to screen for cells in which the fucose transporter gene is disrupted, and ENU (N-ethy (N-nitrosourea) and other chemical mutagens can be used to screen for cells in which the fucose transporter gene has been disrupted by introducing random mutations.
- Screening of cells in which fucose transporter is no longer produced may be performed using the activity of fucose transporter as an indicator, or by transcription or expression of fucose transporter gene as an indicator by Western blotting or Northern blotting. It can also be done.
- the cells in which the fucose transporter gene of the present invention is disrupted can also have animal power in which the fucose transporter gene is knocked out.
- An animal in which the fucose transporter gene has been knocked out can be produced by disrupting the fucose transporter of ES cells by the above-mentioned method and using the ES cell force, for example, the method described in WO02 / 33054. Examples of animals used in this case include, but are not limited to, goats, pigs, hidges, ushis, mice, mice, musters, rats and the like.
- the exogenous protein is an antibody
- the two Hc Fc regions of one antibody molecule When fucose is bound to the N-glycoside-linked sugar chain bound to the sugar chain-binding site, a product is obtained. If such fucose is bound, the antibody has enhanced cytotoxic activity.
- the present invention also includes animals (except humans) that are deficient in both of the fucose transporter genes on the chromosome. By using such an animal, a recombinant polypeptide can be produced in vivo.
- DNA encoding a target protein is introduced into these animals, and the polypeptide is produced in the body of the animal and recovered.
- the “host” in the present invention includes these animals. When animals are used, there are production systems using mammals and insects. Mammalian animals include goats, pigs, hidges, mice, and bushes (Vicki Glaser, SPECTRUM Biotechnology Applications, 1993).
- the target DNA is prepared as a fusion gene with a gene encoding a polypeptide inherently produced in milk such as goat / 3 casein.
- the DNA fragment containing the fusion gene is then injected into a goat embryo and the embryo is transferred to a female goat.
- the desired polypeptide can be obtained from the milk produced by the transgene goat born from the goat that received the embryo or its progeny.
- Hormones may be used in transgenes as appropriate to increase milk production, including polypeptides that are also produced by transgene caps (Ebert, KM et al., Bio / Technology (1994) 12, 699- 702).
- the obtained polypeptide can be isolated in a host cell or extracellular (eg, medium), and purified as a substantially pure and homogeneous polypeptide. Separation and purification of polypeptides are not limited in any way as long as separation and purification methods used in normal polypeptide purification are used. For example, select chromatography column, filter, ultrafiltration, salting out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectric focusing, dialysis, recrystallization, etc. If combined, the polypeptide can be separated and purified. [0061] Examples of chromatography include affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration, reverse phase chromatography, adsorption chromatography, etc. (Strategies for Protein Purification and
- polypeptide can be arbitrarily modified or the peptide can be partially removed by allowing an appropriate protein modifying enzyme to act before or after the polypeptide is purified.
- protein modifying enzyme include trypsin, chymotrypsin, lysyl endobeptidase, protein kinase, darcosidase, and the like.
- a known sequence can be used, or it can be obtained by a method known to those skilled in the art. It is. For example, it can be obtained by cloning a gene encoding a hybridoma-producing antibody that produces a monoclonal antibody, or can be obtained from an antibody library.
- Nobridoma can be produced basically by using a known technique as follows. That is, a desired antigen or a cell expressing the desired antigen is used as a sensitizing antigen, and this is immunized according to a normal immunization method, and the resulting immune cell is fused with a known parent cell by a normal cell fusion method.
- V region variable region cDNA of the antibody variable region (V region) from the obtained mRNA of the hybridoma using reverse transcriptase and ligating it with the DNA encoding the desired antibody constant region (C region).
- C region DNA encoding the desired antibody constant region
- Genes encoding H chains or L chains can be obtained.
- the target full length protein, a partial peptide, etc. can be used.
- Antigens can be prepared by methods known to those skilled in the art, for example, according to methods using baculovirus (eg, W098 / 46777).
- Hypridoma can be prepared according to, for example, the method of Milstein et al. (Kohler, G., and Milstein, C, Methods Enzymol. 1981, 73, 3-46.).
- the antibody expressed and produced as described above can be purified by a known method used in normal protein purification.
- antibodies can be separated and purified by appropriately selecting and combining affinity columns such as protein A columns, chromatography columns, filters, ultrafiltration, salting out, dialysis, etc. (Ant3 ⁇ 4odies A Laboratory Manual. Ed (Harlow, David Lane, Cold Spring Harbor Laboratory, 1988)
- ELISA enzyme-linked immunosorbent assay
- EIA enzyme immunoassay
- RIA radioimmunoassay
- fluorescent immunoassay can be used.
- sugar chain structure of the protein produced using the cells of the present invention can be carried out by the two-dimensional sugar chain map method (Anal. Biochem, 171, 73, (1988), biochemical experiment method 23- Glycoprotein Glycan Research Method can be carried out by the method described in Etsuko Takahashi, Academic Publishing Center (1989) etc.
- sugar chains can also be analyzed by mass spectrometry such as MALD TOF-MS.
- the antibody produced by the method of the present invention is an antibody having increased cytotoxic activity.
- the cytotoxic activity in the present invention refers to, for example, antibody-dependent cell-mediated cytotoxicity
- ADCC activity means cytotoxic activity by the complement system
- ADCC activity means that when a specific antibody is attached to a cell surface antigen of a target cell, 1F ⁇ receptor-bearing cell (immune cell) Etc.) means an activity that binds via Fc ⁇ receptor and damages target cells.
- Whether or not an antibody has ADCC activity or CDC activity can be determined by a known method (for example, Current protocols in Immunology, Chapter 7. Immunologic studies in humans, Editor, John E, Coligan et al., John Wiley & Sons, Inc., (1993)).
- effector cells Specifically, first, effector cells, complement solutions, and target cells are prepared.
- spleen remove the spleen from a mouse such as a CBA / N mouse and isolate the spleen cells in RPMI1640 medium (GIBCO). After washing with the same medium containing 10% urine fetal serum (FBS, manufactured by HyClone), adjust the cell concentration to 5 ⁇ 10 6 / ml to prepare effector cells.
- FBS urine fetal serum
- Baby Rabbit Complement (CEDARLANE) is diluted 10-fold with 10% FBS-containing medium (GIBCO) to prepare a complement solution.
- GEBCO FBS-containing medium
- Spleen cancer cell lines (AsPC-1, Capan-2, etc.) are cultured with 0.2mCi of 51 Cr-sodium chromate (Amersham Pharmacia Biotech) in DMEM medium containing 10% FBS for 1 hour at 37 ° C. Radiolabel. After radiolabelling, the cells are washed 3 times with RPMI1640 medium containing 10% FBS, and the cell concentration is adjusted to 2 ⁇ 10 5 / ml to prepare target cells.
- ADCC activity or CDC activity is measured.
- To measure ADCC activity add 50 ⁇ l of target cells and antibody to a 96-well U-bottom plate (Beckton Dickinson) and allow to react for 15 minutes on ice. Then add effector cells 100 1 and incubate in a carbon dioxide incubator for 4 hours. The final antibody concentration is 0 or 10 g / ml. After incubation, 100 ⁇ l of the supernatant is collected, and the radioactivity is measured with a gamma counter (COBRAIIAUTO-GMMA, MODEL D5005, Packard Instrument Company). Cytotoxic activity (%) can be determined by (A-C) / (B-C) X 100.
- A is the radioactivity (cpm) in each sample
- B is the radioactivity (cpm) in the sample with 1% NP-40 (manufactured by Hanai)
- C is the radioactivity (cpm) of the sample containing only the target cells. Show.
- a target cell and an anti-PepT antibody are added one by one to a 96-well flat bottom plate (manufactured by Becton Dickinson) and allowed to react on ice for 15 minutes. afterwards, Add complement solution 100 1 and incubate in carbon dioxide incubator for 4 hours. The final antibody concentration should be 0 or 3 g / ml. After incubation, collect 1001 supernatant and measure radioactivity with a gamma counter. Cytotoxic activity can be determined in the same manner as ADCC activity measurement.
- Hyg5-BH and Hyg3-NT primers from pcDNA3.1 / Hygro (Invitrogen)
- the BamH I site and TGCGC sequences were added to the 5th side of the start codon of the Hygromycin resistance gene (Hyg 1 ").
- Hyg 1 Hygromycin resistance gene
- HyG 1 was extracted by adding Not I site to the 3 'side including the region up to the SV40 polyA addition signal.
- Ver targeting vector fucose transporter .l (hereinafter, referred to as K01 vector) is PMClDT- A vector (Yagi T, Proc. Natl. Acad. Sci. USA vol.87,
- the mouse pgk-1 gene promoter was excised with EcoR I-Pst I from the pKJ2 vector (Popo H, Biochemical Genetics vol.28, p299—308, 1990) and placed on the EcoR I-Pst I site of pBluescript (Stratagene). Cloning was performed to prepare pBSK-pgk-1.
- Hyg 1 is obtained from pcDNA3.1 / Hygro by PCR with Hyg5- AV and Hyg3- BH primers, and the EcoT22 I site and Kozak sequence are attached to the 5th side of Hyg"".
- Hyg 1 was extracted by adding a BamHI site on the 3 'side including the region up to the signal.
- Hyg r (EcoT22 I- BamH I) fragment pBSK- pgk- 1 of Pst I- BamH I ⁇ enter City site, to produce a pBSK- pgk- 1- Hyg 1 ".
- Targeting vector ver .2 fucose transporter (hereinafter, referred to as K02 vector) from Sma I of No.2,780 the base sequence shown in the 5 'side (SEQ ID NO: 1 of the fucose transporter on pMClDT-A vector No. It was constructed by inserting 4,232 BamHI), 3 side (Sac from No.4,284 to No.10,934), and pgk-to Hyg f fragment, respectively (FIG. 1).
- the K02 vector has Hyg 1 "with the promoter of the pgk-1 gene, so even if only one copy of the vector is introduced into the cell by homologous recombination, it gains resistance to hyalomycin B
- the K02 vector was cleaved with Not I and introduced into the cell.
- the K02 vector caused the fucose transporter to lose 46 base pairs of exon 1 including the start codon and lose its function. It is done.
- pPUR vector (BD Biosciences Inc.) was cleaved with Pst I and BamH I, and inserting the Furagume down HPunZ) cut out PBSK- PGK-1 of Pst I- BamH I site, the pBSK- pgk- 1- Puro r Produced.
- K03 vector Targeting vector ver .3 fucose transporter (hereinafter, referred to as K03 vector) from Sma I of No.2,780 the base sequence shown in the 5 'side (SEQ ID NO: 1 of the fucose transporter on pMClDT-A vector No. 4,232 (BamHI), 3, side (from Sac from No.4,284 to No.10,934), and pgk-1-Puro 1 "fragments were inserted respectively (Fig. 1). -A sequence to which the screening primer shown below was bound was attached in advance to the 3 'end of Puro 1 ".
- the K03 vector was cut with Not I and introduced into cells.
- the K03 vector causes the fucose transporter to lose 46 base pairs in exon 1 including the start codon and lose function.
- CHO-S-SFMII HT- (Invitrogen, cat 12052-098) and HT Supplement (lOOX) (Invitrogen cat. 11067-030) and penicillin streptomycin (Invitrogen cat. 15140-122) were mixed with CHO-S-SFMII HT -1/100 amount of calorie for each capacity. This was subcultured through the DXB11 strain of CHO cells as a culture medium (hereinafter referred to as SFMII (+)), and further cultured after this gene transfer with this SFMIK +). 8 ⁇ 10 6 CHO cells were suspended in 0.8 mL Dulbecco's phosphate buffer (hereinafter abbreviated as PBS; Invitrogen cat 14190-144).
- PBS Dulbecco's phosphate buffer
- the targeting vector was added to the cell suspension, and the cell suspension was transferred to Gene Pulser Cuvette (4 mm) (Bio-Rad cat. 1652088). After standing for 10 minutes on ice, the vector was introduced into the cells by the electoral position method with GENE-PULSER II (BioRad code No. 340BR) under conditions of 1.5 kV and 25 FD. . After the vector was introduced, the cells were suspended in 200 ml of SFMII (+) medium, and the cells were seeded at 100 ⁇ 1 / well in 20 96-well flat-bottom plates (Iwaki cat. 1860-096). CO in the plate
- K01 vector and K02 vector were introduced into CHO cells, respectively, and the vector introduction ability was selected with hygromycin B (Invitrogen cat. 10687-010) 24 hours later.
- Hygromycin B was dissolved in SFMII (+) to 0.3 mg / ml, and 100 1 / well was added.
- CHO cells used for screening are cultured in 96-well flat-bottom plates, and after removing the culture supernatant, add 50 ⁇ l / well of cell lysis buffer and warm to 55 ° C for 2 hours, followed by 95 ° C, 15 By heating for a few minutes, proteinase K was inactivated to form a PCR kit.
- Buffer for cell lysis is 10 X LA buffer per well (attached to Takara LA Taq) 5 1, 10% NP-40 (Roche cat. 1 332 473) 2.5 ⁇ 1, proteinase K (20 mg / ml, Takara cat. 9033) 4 1, and distilled water (Nacala Tester cat. 36421-35) 38.5 ⁇ 1
- PCR reaction mixture is the above PCR sample 1 1, 10 X LA buffer II 51, MgCl
- TP-F4 and THygro-Rl were used as screening primers for screening cells transfected with K01 vector, and TP-F4 and THygro-F1 were used as PCR primers for screening cells transfected with K02 vector.
- PCR of cells into which K01 vector was introduced was pre-heated at 95 ° C for 1 minute, amplified at 95 ° C for 30 seconds, 60 ° C for 30 seconds, and 60 ° C for 2 minutes. The cycle was 40 cycles and double heating at 72 ° C for 7 minutes.
- Primers are as follows. In a sample of cells that have undergone homologous recombination, about 1.6 kb of DNA is amplified for the K01 vector and about 2.0 kb of DNA for the K02 vector.
- TP-F4 was set on the outside of the vector and in the genomic region of the fucose transporter on the 5th side, and THygro-Fl and THygro-Rl were set in Hyg in the vector.
- a total of 918 cells into which the K01 vector had been introduced were analyzed, of which one cell was considered to be a homologous recombinant (the homologous recombination efficiency was approximately 0.1%).
- 537 cells transfected with the K02 vector were analyzed, of which 17 cells were considered to be homologous recombinants.
- Genomic DNA was adjusted to 10 / zg according to the cultured cell strength method, and Southern blotting was performed. Of the nucleotide sequence shown in SEQ ID NO: 1.
- a 387 bp probe was prepared and used for confirmation by Southern blotting. Genomic DNA was cut with Bgl II.
- Bgl-F 5 '-TGT GCT GGG AAT TGA ACC CAG GAC -3 (SEQ ID NO: 11) Reverse primer
- Bgl-R 5 '-CTA CTT GTC TGT GCT TTC TTC C -3' (SEQ ID NO: 12)
- Cleavage with Bgl II results in a band of approximately 3.0 kb from the fucose transporter chromosome, approximately 4.6 kb from the chromosome that has undergone homologous recombination with the KOI vector, and approximately 5.0 kb of chromosomal force that has undergone homologous recombination with the K02 vector.
- Fig. 2 shows the structure of the band that appears after cutting out with Bgl II after the first stage of knockout.
- Fig. 3 shows the data when the Southern plot was actually performed.
- TPS- F1 5,-CTC GAC TCG TCC CTA TTA GGC AAC AGC -3 (SEQ ID NO: 13) Reverse primer
- SHygro- R1 5,-TCA GAG GCA GTG GAG CCT CCA GTC AGC -3 (SEQ ID NO: 1 4)
- TP-F4 was used as the forward primer and RSGR-A was used as the reverse primer.
- PCR conditions include preheating at 95 ° C for 1 minute, 95 ° C for 30 seconds, 60 ° C for 30 seconds, 72 ° C for 2 minutes, 35 cycles of amplification cycle, and 72 ° C 7 minutes double heating.
- approximately 1.6 kb of DNA is amplified. This PCR detected cells that had undergone homologous recombination with the K03 vector, and confirmed that homologous recombination with the K02 vector remained.
- Method 1 616 cells were analyzed, of which 18 cells were considered to be homologous recombinants (homologous recombination efficiency was 2.9%) ( Figure 4).
- Method 2 524 cells were analyzed, of which 2 cells were considered to be homologous recombinants (homologous recombination efficiency was approximately 0.4%).
- Method 3 analyzed 382 cells, of which 7 cells were considered to be homologous recombinants (homologous recombination efficiency was approximately 1.8%).
- FIG. 5 shows the Southern blot analysis (Fig. 5) of the obtained clones and the expression of fucose.
- Figure 6 shows the results for wild / KO, and Figure 7 shows the results for KO / KO.
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006548646A JPWO2006067847A1 (ja) | 2004-12-22 | 2004-12-22 | フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法 |
US11/793,712 US20090061485A1 (en) | 2004-12-22 | 2004-12-22 | Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited |
EP10161340A EP2208783A1 (en) | 2004-12-22 | 2004-12-22 | Method of producing an antibody using a cell in which the function of fucose transporter is inhibited |
PCT/JP2004/019261 WO2006067847A1 (ja) | 2004-12-22 | 2004-12-22 | フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法 |
EP04807618A EP1829961A4 (en) | 2004-12-22 | 2004-12-22 | PROCESS FOR PREPARING ANTIBODY USING A CELL WHOSE FUCOSE CARRIER FUNCTION IS INHIBITED |
EP05800043A EP1829962A4 (en) | 2004-12-22 | 2005-10-26 | METHOD FOR THE PRODUCTION OF AN ANTIBODY BY USING A CELL WITH HARDENED FUCOSET TRANSPORT FUNCTION |
US11/793,649 US20080166756A1 (en) | 2004-12-22 | 2005-10-26 | Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited |
EP10162932A EP2216404A1 (en) | 2004-12-22 | 2005-10-26 | Method of producing an antibody using a cell in which the function of fucose transporter is inhibited |
PCT/JP2005/020060 WO2006067913A1 (ja) | 2004-12-22 | 2005-10-26 | フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法 |
JP2006548717A JPWO2006067913A1 (ja) | 2004-12-22 | 2005-10-26 | フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2004/019261 WO2006067847A1 (ja) | 2004-12-22 | 2004-12-22 | フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006067847A1 true WO2006067847A1 (ja) | 2006-06-29 |
Family
ID=36601460
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/019261 WO2006067847A1 (ja) | 2004-12-22 | 2004-12-22 | フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法 |
PCT/JP2005/020060 WO2006067913A1 (ja) | 2004-12-22 | 2005-10-26 | フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/020060 WO2006067913A1 (ja) | 2004-12-22 | 2005-10-26 | フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20090061485A1 (ja) |
EP (4) | EP1829961A4 (ja) |
JP (2) | JPWO2006067847A1 (ja) |
WO (2) | WO2006067847A1 (ja) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008020586A1 (en) | 2006-08-14 | 2008-02-21 | Forerunner Pharma Research Co., Ltd. | Diagnosis and treatment of cancer using anti-desmoglein-3 antibody |
WO2008047925A1 (fr) | 2006-10-20 | 2008-04-24 | Forerunner Pharma Research Co., Ltd. | Composition pharmaceutique comprenant un anticorps anti-hb-egf comme ingrédient actif |
WO2008093688A1 (ja) | 2007-01-30 | 2008-08-07 | Forerunner Pharma Research Co., Ltd. | キメラFcγレセプター及び該レセプターを用いたADCC活性測定方法 |
WO2009001840A1 (ja) | 2007-06-25 | 2008-12-31 | Forerunner Pharma Research Co., Ltd. | ADCC活性又はCDC活性を有する抗Prominin-1抗体 |
WO2009087978A1 (ja) | 2008-01-11 | 2009-07-16 | The University Of Tokyo | 抗cldn6抗体 |
WO2009125825A1 (ja) | 2008-04-11 | 2009-10-15 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
WO2011021381A1 (ja) | 2009-08-17 | 2011-02-24 | 株式会社未来創薬研究所 | 抗hb-egf抗体を有効成分として含む医薬組成物 |
WO2011122011A2 (en) | 2010-03-30 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Antibodies with modified affinity to fcrn that promote antigen clearance |
WO2012067176A1 (ja) | 2010-11-17 | 2012-05-24 | 中外製薬株式会社 | 血液凝固第viii因子の機能を代替する機能を有する多重特異性抗原結合分子 |
WO2012073992A1 (ja) | 2010-11-30 | 2012-06-07 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
WO2013046704A2 (en) | 2011-09-30 | 2013-04-04 | Chugai Seiyaku Kabushiki Kaisha | THERAPEUTIC ANTIGEN-BINDING MOLECULE WITH A FcRn-BINDING DOMAIN THAT PROMOTES ANTIGEN CLEARANCE |
WO2013047748A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
WO2013118858A1 (ja) | 2012-02-09 | 2013-08-15 | 中外製薬株式会社 | 抗体のFc領域改変体 |
WO2015187779A1 (en) | 2014-06-03 | 2015-12-10 | Xbiotech, Inc. | Compositions and methods for treating and preventing staphylococcus aureus infections |
WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
WO2017046994A1 (en) | 2015-09-18 | 2017-03-23 | Chugai Seiyaku Kabushiki Kaisha | Il-8-binding antibodies and uses thereof |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602004028249D1 (de) * | 2003-06-18 | 2010-09-02 | Chugai Pharmaceutical Co Ltd | Fucosetransporter |
ATE486610T1 (de) * | 2004-07-09 | 2010-11-15 | Chugai Pharmaceutical Co Ltd | Anti-glypican-3-antikörper |
TWI468514B (zh) * | 2004-10-26 | 2015-01-11 | Chugai Pharmaceutical Co Ltd | Sugar chain modified phosphatidylinositol glyphosyl 3 antibody |
US10011858B2 (en) * | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US20070087005A1 (en) * | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
DK3056568T3 (da) | 2006-03-31 | 2021-11-01 | Chugai Pharmaceutical Co Ltd | Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik |
ES2654040T3 (es) | 2006-03-31 | 2018-02-12 | Chugai Seiyaku Kabushiki Kaisha | Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos |
AU2007312367B2 (en) | 2006-10-12 | 2012-09-06 | Chugai Seiyaku Kabushiki Kaisha | Diagnosis and treatment of cancer using anti-EREG antibody |
CL2008002886A1 (es) * | 2007-09-26 | 2009-12-04 | Chugai Pharmaceutical Co Ltd | Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende. |
CN106519025B (zh) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
AU2008305851B2 (en) * | 2007-09-28 | 2014-12-18 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican-3 antibody having improved kinetics in plasma |
BRPI0821110B8 (pt) | 2007-12-05 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo |
CL2009000647A1 (es) * | 2008-04-04 | 2010-06-04 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto. |
ES2458541T3 (es) | 2008-05-02 | 2014-05-06 | Seattle Genetics, Inc. | Métodos y composiciones para elaborar anticuerpos y derivados de anticuerpos con fucosilación del núcleo reducida |
MX2010014319A (es) * | 2008-07-08 | 2011-05-19 | Geneuro Sa | Uso terapeutico de ligando especifico en enfermedades asociadas con msrv. |
AU2009290591B2 (en) * | 2008-09-15 | 2015-10-01 | Haier Us Appliance Solutions, Inc. | Energy management of clothes washer appliance |
ES2592216T3 (es) | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
BRPI0923652A2 (pt) | 2008-12-26 | 2016-10-18 | Forerunner Pharma Res Co Ltd | diagnóstico e tratamento de câncer usando anticorpo anti-lgr7 |
JP5787446B2 (ja) | 2009-03-19 | 2015-09-30 | 中外製薬株式会社 | 抗体定常領域改変体 |
WO2010107110A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
EP2436397B1 (en) | 2009-05-29 | 2017-05-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition containing antagonist of egf family ligand as component |
LT3023438T (lt) | 2009-09-03 | 2020-05-11 | Merck Sharp & Dohme Corp. | Anti-gitr antikūnai |
WO2011035884A1 (en) | 2009-09-22 | 2011-03-31 | Volker Sandig | Process for producing molecules containing specialized glycan structures |
WO2011037158A1 (ja) | 2009-09-24 | 2011-03-31 | 中外製薬株式会社 | 抗体定常領域改変体 |
US10435458B2 (en) | 2010-03-04 | 2019-10-08 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variants with reduced Fcgammar binding |
MX356671B (es) | 2010-08-05 | 2018-06-08 | Seattle Genetics Inc | Métodos para inhibir fucosilación de proteína in vivo utilizando análogos de fucosa. |
MX352889B (es) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Anticuerpo de fc especifico para fcyriib. |
US20140193420A1 (en) | 2011-04-18 | 2014-07-10 | Chugai Seiyaku Kabushiki Kaisha | Diagnosis and treatment of cancer using anti-itm2a antibody |
BR112013032630B1 (pt) | 2011-06-30 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Polipeptídeo heterodimerizado compreendendo região fc de igg |
KR102239138B1 (ko) | 2011-09-30 | 2021-04-12 | 추가이 세이야쿠 가부시키가이샤 | 표적 항원에 대한 면역응답을 유도하는 항원 결합 분자 |
WO2013047752A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 抗原の消失を促進する抗原結合分子 |
TWI593705B (zh) | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
EP2804946A4 (en) * | 2012-01-20 | 2016-05-25 | Agency Science Tech & Res | RECOMBINANT CHO GMT PROTEIN EXPRESSION |
JP6138108B2 (ja) | 2012-02-24 | 2017-05-31 | 中外製薬株式会社 | FcγRIIBを介して抗原の消失を促進する抗原結合分子 |
EP2832856A4 (en) | 2012-03-29 | 2016-01-27 | Chugai Pharmaceutical Co Ltd | ANTI-LAMP5 ANTIBODIES AND USE THEREOF |
DK2857420T3 (da) | 2012-05-30 | 2020-11-23 | Chugai Pharmaceutical Co Ltd | Målvævsspecifikt antigenbindende molekyle |
US11142563B2 (en) | 2012-06-14 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing modified Fc region |
US10350228B2 (en) | 2012-08-23 | 2019-07-16 | Seattle Genetics, Inc. | Treatment of sickle cell disease and inflammatory conditions |
TWI693073B (zh) | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑 |
EP3557260B1 (en) | 2012-12-21 | 2022-05-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy |
DK2940135T5 (da) | 2012-12-27 | 2021-09-20 | Chugai Pharmaceutical Co Ltd | Heterodimeriseret polypeptid |
US11267868B2 (en) | 2013-04-02 | 2022-03-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
CN105517571A (zh) | 2013-06-24 | 2016-04-20 | 中外制药株式会社 | 含有人源化抗上皮调节蛋白抗体作为有效成分的腺癌以外的非小细胞肺癌的治疗药 |
CN104436157A (zh) | 2013-09-23 | 2015-03-25 | 恩金生物有限公司 | 流感疫苗和治疗 |
BR112016006197B1 (pt) | 2013-09-27 | 2023-04-11 | Chugai Seiyaku Kabushiki Kaisha | Método para produzir um anticorpo biespecífico de polipeptídeos |
SG11201604495PA (en) | 2013-12-04 | 2016-07-28 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules |
EP3107567A4 (en) * | 2014-02-19 | 2017-10-25 | Cangene Corporation | Methods of modulating an immune response |
SG11201609014TA (en) | 2014-05-08 | 2016-12-29 | Chugai Pharmaceutical Co Ltd | Gpc3 -targeting drug which is administered to patient responsive to gpc3-targeting drug therapy |
BR112017003263A2 (pt) | 2014-09-16 | 2017-11-28 | Ovascience Inc | anticorpos anti-vasa, e métodos de produção e utilização dos mesmos |
WO2016049183A1 (en) * | 2014-09-24 | 2016-03-31 | Aerpio Therapeutics, Inc. | Ve-ptp extracellular domain antibodies delivered by a gene therapy vector |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
PE20221834A1 (es) | 2014-12-19 | 2022-11-29 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina |
RU2746356C2 (ru) | 2014-12-19 | 2021-04-12 | Чугаи Сейяку Кабусики Кайся | Антитела к с5 и способы их применения |
TWI805046B (zh) | 2015-02-27 | 2023-06-11 | 日商中外製藥股份有限公司 | Il-6受體抗體用於製備醫藥組成物的用途 |
EP3279216A4 (en) | 2015-04-01 | 2019-06-19 | Chugai Seiyaku Kabushiki Kaisha | PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER |
WO2017002934A1 (ja) | 2015-07-01 | 2017-01-05 | 中外製薬株式会社 | Gpc3標的治療剤が有効である患者に投与されるgpc3標的治療剤 |
US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
WO2017115773A1 (ja) | 2015-12-28 | 2017-07-06 | 中外製薬株式会社 | Fc領域含有ポリペプチドの精製を効率化するための方法 |
TW202342540A (zh) | 2016-03-14 | 2023-11-01 | 日商中外製藥股份有限公司 | 用於癌之治療的細胞傷害誘導治療劑 |
CN116251182A (zh) | 2016-08-05 | 2023-06-13 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
JP7185884B2 (ja) | 2017-05-02 | 2022-12-08 | 国立研究開発法人国立精神・神経医療研究センター | Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法 |
CA3110255A1 (en) * | 2018-08-29 | 2020-03-05 | United Biopharma Inc | Afucosylated antibodies and manufacture thereof |
US20220153875A1 (en) | 2019-03-19 | 2022-05-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain |
US20230416371A1 (en) | 2020-08-28 | 2023-12-28 | Chugai Seiyaku Kabushiki Kaisha | Heterodimer fc polypeptide |
WO2022270612A1 (ja) | 2021-06-25 | 2022-12-29 | 中外製薬株式会社 | 抗ctla-4抗体の使用 |
JP7472405B2 (ja) | 2021-06-25 | 2024-04-22 | 中外製薬株式会社 | 抗ctla-4抗体 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003085118A1 (fr) * | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production de composition anticorps |
WO2003085102A1 (fr) * | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cellule avec inhibition ou suppression de l'activite de la proteine participant au transport du gdp-fucose |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE8130T1 (de) * | 1980-08-25 | 1984-07-15 | Kabivitrum Ab | Peptidsubstrate zum bestimmen der proteaseaktivitaet. |
JPS58201994A (ja) | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
DK1024191T3 (da) | 1991-12-02 | 2008-12-08 | Medical Res Council | Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker |
CA2131151A1 (en) | 1992-03-24 | 1994-09-30 | Kevin S. Johnson | Methods for producing members of specific binding pairs |
JP2651316B2 (ja) * | 1992-05-26 | 1997-09-10 | 理化学研究所 | 相同組換え細胞選別法 |
ATE381614T1 (de) | 1992-07-24 | 2008-01-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
CA2177367A1 (en) | 1993-12-03 | 1995-06-08 | Andrew David Griffiths | Recombinant binding proteins and peptides |
AU701342B2 (en) | 1994-07-13 | 1999-01-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
ES2304786T3 (es) | 1995-04-27 | 2008-10-16 | Amgen Fremont Inc. | Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados. |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
US7105315B2 (en) * | 1999-06-16 | 2006-09-12 | Incyte Genomics, Inc. | Transmembrane protein differentially expressed in cancer |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
WO2001009316A1 (fr) * | 1999-07-29 | 2001-02-08 | Helix Research Institute | Nouveaux genes codant la proteine kinase / proteine phosphatase |
WO2001009345A1 (fr) * | 1999-07-29 | 2001-02-08 | Helix Research Institute | Nouveaux genes codant des proteines kinase et des proteines phosphatase |
US6908748B2 (en) * | 1999-07-29 | 2005-06-21 | Kenji Sobue | Genes associated with the maintenance of differentiation of smooth muscle cells |
CA2385162A1 (en) * | 1999-09-30 | 2001-04-05 | William L. Fodor | Compositions and methods for altering gene expression |
US20020197679A1 (en) * | 2000-06-20 | 2002-12-26 | Tang Y. Tom | Novel nucleic acids and polypeptides |
AU2001295982A1 (en) | 2000-10-20 | 2002-04-29 | Chugai Seiyaku Kabushiki Kaisha | Polybeta2 knockout animals |
NZ539459A (en) * | 2002-11-08 | 2009-02-28 | Kirin Pharma Kk | Transgenic ungulates having reduced prion protein activity and uses thereof |
DE602004028249D1 (de) * | 2003-06-18 | 2010-09-02 | Chugai Pharmaceutical Co Ltd | Fucosetransporter |
WO2005014651A1 (ja) | 2003-08-11 | 2005-02-17 | Chugai Seiyaku Kabushiki Kaisha | 糖鎖改変抗hm1.24抗体 |
-
2004
- 2004-12-22 US US11/793,712 patent/US20090061485A1/en not_active Abandoned
- 2004-12-22 EP EP04807618A patent/EP1829961A4/en not_active Withdrawn
- 2004-12-22 WO PCT/JP2004/019261 patent/WO2006067847A1/ja active Application Filing
- 2004-12-22 JP JP2006548646A patent/JPWO2006067847A1/ja active Pending
- 2004-12-22 EP EP10161340A patent/EP2208783A1/en not_active Withdrawn
-
2005
- 2005-10-26 EP EP05800043A patent/EP1829962A4/en not_active Withdrawn
- 2005-10-26 JP JP2006548717A patent/JPWO2006067913A1/ja active Pending
- 2005-10-26 EP EP10162932A patent/EP2216404A1/en not_active Withdrawn
- 2005-10-26 US US11/793,649 patent/US20080166756A1/en not_active Abandoned
- 2005-10-26 WO PCT/JP2005/020060 patent/WO2006067913A1/ja active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003085118A1 (fr) * | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production de composition anticorps |
WO2003085102A1 (fr) * | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cellule avec inhibition ou suppression de l'activite de la proteine participant au transport du gdp-fucose |
Non-Patent Citations (9)
Title |
---|
FREEZE H.H.: "Update and perspectives on congenital disorders of glycosylation", GLYCOBIOLOGY, vol. 11, no. 12, 2001, pages 129R - 143R, XP003005282 * |
LUBKE T. ET AL.: "Complementation cloning identifies CDG-IIc, a new type of congenital disorders of glycosylation, as a GDP-fucose transporter deficiency", NAT. GENET., vol. 28, no. 1, 2001, pages 73 - 76, XP003005283 * |
LUHN K. ET AL.: "The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter", NAT. GENET., vol. 28, no. 1, 2001, pages 69 - 72, XP002970288 * |
OKADA H. ET AL.: "Gene Targeting", SHIN IDENSHI KOGAKU HANDBOOK, 1996, pages 277 - 283, XP003005281 * |
PENNINGTON S.L. ET AL.: "Gene targeting in Chinese hamster ovary cells is conservative", PROC. NATL. ACAD. SCI. USA, vol. 88, no. 21, 1991, pages 9498 - 9502, XP002999549 * |
PUGLIELLI L. ET AL.: "Reconstitution, identification, and purification of the rat liver golgi membrane GDP-fucose transporter", J. BIOL. CHEM., vol. 274, no. 50, 1999, pages 35596 - 35600, XP002970290 * |
See also references of EP1829961A4 * |
YAGI T. ET AL.: "Homologous recombinatioin at c-fyn locus of mouse embryonic stem cells with use of diphtheria toxin A-fragment gene in negative selection", PROC. NATL. ACAD. SCI. USA, vol. 87, no. 24, 1990, pages 9918 - 9922, XP002999550 * |
YAMANE-OHNUKI N. ET AL.: "Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity", BIOTECHNOL. BIOENG., vol. 87, no. 5, 5 September 2004 (2004-09-05), pages 614 - 622, XP002983758 * |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008020586A1 (en) | 2006-08-14 | 2008-02-21 | Forerunner Pharma Research Co., Ltd. | Diagnosis and treatment of cancer using anti-desmoglein-3 antibody |
EP3111955A1 (en) | 2006-08-14 | 2017-01-04 | Chugai Seiyaku Kabushiki Kaisha | Diagnosis and treatment of cancer using anti-desmoglein-3 antibody |
EP3040347A2 (en) | 2006-10-20 | 2016-07-06 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient |
WO2008047925A1 (fr) | 2006-10-20 | 2008-04-24 | Forerunner Pharma Research Co., Ltd. | Composition pharmaceutique comprenant un anticorps anti-hb-egf comme ingrédient actif |
WO2008093688A1 (ja) | 2007-01-30 | 2008-08-07 | Forerunner Pharma Research Co., Ltd. | キメラFcγレセプター及び該レセプターを用いたADCC活性測定方法 |
WO2009001840A1 (ja) | 2007-06-25 | 2008-12-31 | Forerunner Pharma Research Co., Ltd. | ADCC活性又はCDC活性を有する抗Prominin-1抗体 |
WO2009087978A1 (ja) | 2008-01-11 | 2009-07-16 | The University Of Tokyo | 抗cldn6抗体 |
EP4282428A2 (en) | 2008-01-11 | 2023-11-29 | The University of Tokyo | Anti-cldn6 antibody |
EP3064512A2 (en) | 2008-01-11 | 2016-09-07 | The University of Tokyo | Anti-cldn6 antibody |
EP3514180A1 (en) | 2008-04-11 | 2019-07-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
WO2009125825A1 (ja) | 2008-04-11 | 2009-10-15 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
EP4238993A2 (en) | 2008-04-11 | 2023-09-06 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
EP2708558A2 (en) | 2008-04-11 | 2014-03-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
EP2708559A2 (en) | 2008-04-11 | 2014-03-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
EP3521311A1 (en) | 2008-04-11 | 2019-08-07 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
EP3056513A1 (en) | 2008-04-11 | 2016-08-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
WO2011021381A1 (ja) | 2009-08-17 | 2011-02-24 | 株式会社未来創薬研究所 | 抗hb-egf抗体を有効成分として含む医薬組成物 |
EP3181581A1 (en) | 2010-03-30 | 2017-06-21 | Chugai Seiyaku Kabushiki Kaisha | Antibodies with modified affinity to fcrn that promote antigen clearance |
EP3702368A1 (en) | 2010-03-30 | 2020-09-02 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecules that promote antigen clearance |
WO2011122011A2 (en) | 2010-03-30 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Antibodies with modified affinity to fcrn that promote antigen clearance |
WO2012067176A1 (ja) | 2010-11-17 | 2012-05-24 | 中外製薬株式会社 | 血液凝固第viii因子の機能を代替する機能を有する多重特異性抗原結合分子 |
EP3318633A1 (en) | 2010-11-17 | 2018-05-09 | Chugai Seiyaku Kabushiki Kaisha | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
WO2012073992A1 (ja) | 2010-11-30 | 2012-06-07 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
EP4231014A2 (en) | 2010-11-30 | 2023-08-23 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
WO2013046704A2 (en) | 2011-09-30 | 2013-04-04 | Chugai Seiyaku Kabushiki Kaisha | THERAPEUTIC ANTIGEN-BINDING MOLECULE WITH A FcRn-BINDING DOMAIN THAT PROMOTES ANTIGEN CLEARANCE |
EP3549956A2 (en) | 2011-09-30 | 2019-10-09 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic antigen-binding molecule with a fcrn-binding domain that promotes antigen clearance |
EP3939996A1 (en) | 2011-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
WO2013047748A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
EP4324850A2 (en) | 2011-09-30 | 2024-02-21 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic antigen-binding molecule with a fcrn-binding domain that promotes antigen clearance |
WO2013118858A1 (ja) | 2012-02-09 | 2013-08-15 | 中外製薬株式会社 | 抗体のFc領域改変体 |
WO2015187779A1 (en) | 2014-06-03 | 2015-12-10 | Xbiotech, Inc. | Compositions and methods for treating and preventing staphylococcus aureus infections |
EP3970747A2 (en) | 2014-06-03 | 2022-03-23 | XBiotech Inc. | Compositions and methods for treating and preventing staphylococcus aureus infections |
WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
EP3816179A2 (en) | 2015-02-05 | 2021-05-05 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant comprising a modified fcrn-binding domain |
WO2017046994A1 (en) | 2015-09-18 | 2017-03-23 | Chugai Seiyaku Kabushiki Kaisha | Il-8-binding antibodies and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1829962A4 (en) | 2008-06-11 |
EP1829962A1 (en) | 2007-09-05 |
EP1829961A4 (en) | 2008-06-04 |
JPWO2006067847A1 (ja) | 2008-06-12 |
US20090061485A1 (en) | 2009-03-05 |
US20080166756A1 (en) | 2008-07-10 |
JPWO2006067913A1 (ja) | 2008-06-12 |
EP2216404A1 (en) | 2010-08-11 |
WO2006067913A1 (ja) | 2006-06-29 |
EP1829961A1 (en) | 2007-09-05 |
EP2208783A1 (en) | 2010-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006067847A1 (ja) | フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法 | |
EP1652925B1 (en) | IgM PRODUCTION BY TRANSFORMED CELLS AND METHODS FOR QUANTIFYING SAID IgM PRODUCTION | |
JP4794457B2 (ja) | 糖鎖改変抗グリピカン3抗体 | |
US8546546B2 (en) | Anti-Muc 17 antibody | |
US20110070614A1 (en) | Fucose transporter | |
US10471146B2 (en) | Cancer-cell-specific anti-transmembrane protein 180 antibody, anticancer drug, and cancer testing method | |
BRPI0818165B1 (pt) | método de produção recombinante de uma imunoglobulina heteróloga em células cho que é secretada para o meio de cultura | |
JP2010155841A (ja) | 細胞死誘導剤 | |
WO2008072723A1 (ja) | 抗Claudin3モノクローナル抗体およびそれを用いる癌の治療および診断 | |
JP5395767B2 (ja) | トランスポーター遺伝子oatp−b、c、d、およびe | |
WO2001023556A1 (fr) | Nouvelle proteine receptrice d'hemopoietine (nr12) | |
JP4799405B2 (ja) | 細胞死誘導剤 | |
JP4938263B2 (ja) | 一本鎖抗体によるサイトゾルタンパク質の機能阻害法およびその利用 | |
JP4794303B2 (ja) | 固形腫瘍治療剤 | |
JP2008099690A (ja) | 新規ヘモポエチン受容体蛋白質、nr12 | |
WO2004039981A1 (ja) | マスト細胞由来の膜タンパク質 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006548646 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11793712 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004807618 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2004807618 Country of ref document: EP |